InflaRx NV (IFRX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:InflaRx NV (IFRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8154
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
InflaRx NV (InflaRx) is a clinical-stage biopharmaceutical company that develops therapies in the field of acute and chronic inflammation. The company offers development of monoclonal antibodies targeting activation products of the complement system for application in threatening inflammatory diseases and certain orhan drug indications. Its pipeline products includes IFX-1 and IFX-2. InflaRx operates in various research and development programs in life science sectors. The company offers antibodies that are able to fulfil requirements determined by InflaRx for generation of suitable drug candidates. It offers research services through collaboration with universities and biotech companies. InflaRx is headquartered in Jena, Germany.

InflaRx NV (IFRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
InflaRx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
InflaRx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
InflaRx NV, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
InflaRx Raises USD55 Million in Series D Financing 10
InflaRx Raises USD34 Million in Series C Venture Financing 11
InflaRx Raises Funds through Series B Financing Round 12
Partnerships 13
InflaRx Enters into Co-Development Agreement with Beijing Defengrei Biotechnology 13
Equity Offering 14
InflaRx Raises USD117.3 Million in Public Offering of Shares 14
InflaRx Raises USD100 Million in IPO 16
InflaRx NV – Key Competitors 17
InflaRx NV – Key Employees 18
InflaRx NV – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Aug 09, 2018: InflaRx reports second quarter 2018 financial & operating results 20
May 17, 2018: InflaRx Reports First Quarter 2018 Financial & Operating Results 21
Mar 29, 2018: InflaRx Full Year 2017 Financial & Operating Results 23
Corporate Communications 24
Feb 06, 2018: InflaRx Names Tony Gibney As Board Director 24
Jun 21, 2017: InflaRx Promotes Othmar Zenker, M.D. to Newly Created Position of Chief Medical Officer 25
Clinical Trials 26
Mar 08, 2018: InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa 26
Jan 09, 2018: InflaRx Receives IND Acceptance To Proceed With A Phase IIb Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa 27
Sep 07, 2017: InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa 28
Jan 04, 2017: InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
InflaRx NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
InflaRx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
InflaRx NV, Deals By Therapy Area, 2012 to YTD 2018 8
InflaRx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
InflaRx Raises USD55 Million in Series D Financing 10
InflaRx Raises USD34 Million in Series C Venture Financing 11
InflaRx Raises Funds through Series B Financing Round 12
InflaRx Enters into Co-Development Agreement with Beijing Defengrei Biotechnology 13
InflaRx Raises USD117.3 Million in Public Offering of Shares 14
InflaRx Raises USD100 Million in IPO 16
InflaRx NV, Key Competitors 17
InflaRx NV, Key Employees 18
InflaRx NV, Other Locations 19

List of Figures
InflaRx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
InflaRx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[InflaRx NV (IFRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Exact Holding N.V.:企業の戦略的SWOT分析
    Exact Holding N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • The Jackson Laboratory:製薬・医療:M&Aディール及び事業提携情報
    Summary The Jackson Laboratory (JAX) is a biomedical research center that offers clinical genomic solutions. The center provides breeding and rederivation services. It offers cryopreservation and recovery services such as sperm cryopreservation, on-site sperm cryopreservation, embryo cryopreservatio …
  • Albany Molecular Research Inc-製薬・医療分野:企業M&A・提携分析
    Summary Albany Molecular Research Inc (AMRI) is a contract research and manufacturing organization. Its service portfolio drug discovery and development, manufacturing of Active Pharmaceutical Ingredients (API); process scale up development of fine chemicals and aseptic filling services for preclini …
  • Consun Pharmaceutical Group Ltd (1681):製薬・医療:M&Aディール及び事業提携情報
    Summary Consun Pharmaceutical Group Ltd (Consun Pharmaceutical) is a pharmaceutical company that manufactures and distributes Chinese medicines. The company offers gadopentetate injection, cetirizine hydrochloride oral solution, iron dextran oral solution, uremic granules, compound amino acid inject …
  • Aequus Pharmaceuticals Inc (AQS):企業の財務・戦略的SWOT分析
    Summary Aequus Pharmaceuticals Inc (Aequus Pharmaceuticals) is a drug discovery and development company that develops differentiated drugs. The company’s pipeline products include AQS304 finds application in the treatment of neurological disorders, and AQS303 is used for the treatment of treatment o …
  • Sunesis Pharmaceuticals Inc (SNSS):製薬・医療:M&Aディール及び事業提携情報
    Summary Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company's Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). …
  • TDC A/S:企業の戦略・SWOT・財務情報
    TDC A/S - Strategy, SWOT and Corporate Finance Report Summary TDC A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • IJM Land Berhad:企業の戦略・SWOT・財務情報
    IJM Land Berhad - Strategy, SWOT and Corporate Finance Report Summary IJM Land Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Telecom Italia S.p.A.:企業の戦略・SWOT・財務情報
    Telecom Italia S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Telecom Italia S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • e.l.f. Beauty, Inc. (ELF):企業の財務・戦略的SWOT分析
    e.l.f. Beauty, Inc. (ELF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • FMC Corp (FMC):企業の財務・戦略的SWOT分析
    FMC Corp (FMC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Black Rock Mining Ltd (BKT):企業の財務・戦略的SWOT分析
    Summary Black Rock Mining Ltd (BRML), formerly Green Rock Energy Ltd, is a mining and mineral exploration company. The company carries out the business of acquisition, exploration, and development of graphite properties. It also holds interest in Mahenge Graphite Project which includes high-grade fl …
  • Miragen Therapeutics Inc (MGEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Miragen Therapeutics, Inc. (Miragen) is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company is developing its pipeline products for the treatment of Cutaneous T-Cell Lymphoma (CTCL), …
  • Theravasc Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Theravasc Inc (Theravasc) is a pharmaceutical company that develops treatments for various chronic medical diseases using oral formulation of sodium nitrite. The company’s product includes TV1001SR, a coated oral formulation of sodium nitrite for the treatment of peripheral artery diseases a …
  • Enterprise Rent-A-Car Company:企業の戦略・SWOT・財務分析
    Enterprise Rent-A-Car Company - Strategy, SWOT and Corporate Finance Report Summary Enterprise Rent-A-Car Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Bulgarian Telecommunications Company (VIVACOM):企業の戦略的SWOT分析
    Bulgarian Telecommunications Company (VIVACOM) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Blokker Holdings N.V.:企業の戦略的SWOT分析
    Blokker Holdings N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Viking Therapeutics Inc (VKTX):企業の財務・戦略的SWOT分析
    Summary Viking Therapeutics Inc (Viking Therapeutics) is a clinical-stage biopharmaceutical company that develops novel therapies for patients suffering from metabolic and endocrine disorders. The company’s lead clinical program product candidate include VK5211, an orally available, non-steroidal se …
  • ObsEva SA (OBSV):製薬・医療:M&Aディール及び事業提携情報
    Summary ObsEva SA (ObsEva) is a clinical-stage biopharmaceutical company that develops and commercializes drugs for women’s reproductive health and pregnancy. The company's product portfolio comprises pipeline products which is being developed to control preterm labor by reducing inflammation, decre …
  • Miltenyi Biotec GmbH-医療機器分野:企業M&A・提携分析
    Summary Miltenyi Biotec GmbH (Miltenyi) is a biotechnology company which provides biomedical research and cellular therapy products for cell isolation, flow cytometry, sample preparation and cell culture. The company's services include sample preparation, cell separation, flow cytometry, cell cultur …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆